FDA approves Persimmon Squibb's PD-1 mono-anti-Opdivo and CTLA-4 mono-anti-Yervoy combination, first-line treatment of non-small cell lung cancer
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Bristol Myers Squibb announced that the FDA has approved a combination of its PD-1 mono-antiOpdivo (nivolumab) and CTLA-4 monoantigen Yervoy (ipilimumab) to treat patients with metastatic non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic mutationsthis approval is based on the results of the CheckMate-227 studyThe results of the first part of CheckMate -227 showed that patients treated with Opdivo and Yervoy had a higher overall survival (OS) during at least 29.3 months of follow-up compared to chemotherapy, with median sylwed sons of OS at 14.9 months and 17.1 months, respectively33 percent of patients treated with Opdivo plus Yervoy were still alive over an average of 43.1 months, compared with 22 percent in the chemotherapy groupa spokesman for the company said the cost of nine doses of Opdivo and three doses of Yervoy treatment was about $104,233Earlier this month, BMS said Opdivo's sales fell 2 percent to $1.8 billion in the first quarter, while Yervoy's sales were $396 million, up 3 percent from a year earlier
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
